Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Neurosurg. 2011 Mar;114(3):801-7. doi: 10.3171/2010.8.JNS10674. Epub 2010 Aug 27.
Stereotactic radiosurgery (SRS) is an important management option for patients with small- and medium-sized vestibular schwannomas. To assess the potential role of SRS in larger tumors, the authors reviewed their recent experience.
Between 1994 and 2008, 65 patients with vestibular schwannomas between 3 and 4 cm in one extracanalicular maximum diameter (median tumor volume 9 ml) underwent Gamma Knife surgery. Seventeen patients (26%) had previously undergone resection.
The median follow-up duration was 36 months (range 1-146 months). At the first planned imaging follow-up at 6 months, 5 tumors (8%) were slightly expanded, 53 (82%) were stable in size, and 7 (11%) were smaller. Two patients (3%) underwent resection within 6 months due to progressive symptoms. Two years later, with 63 tumors overall after the 2 post-SRS resections, 16 tumors (25%) had a volume reduction of more than 50%, 22 (35%) tumors had a volume reduction of 10-50%, 18 (29%) were stable in volume (volume change < 10%), and 7 (11%) had larger volumes (5 of the 7 patients underwent resection and 1 of the 7 underwent repeat SRS). Eighteen (82%) of 22 patients with serviceable hearing before SRS still had serviceable hearing after SRS more than 2 years later. Three patients (5%) developed symptomatic hydrocephalus and underwent placement of a ventriculoperitoneal shunt. In 4 patients (6%) trigeminal sensory dysfunction developed, and in 1 patient (2%) mild facial weakness (House-Brackmann Grade II) developed after SRS. In univariate analysis, patients who had a previous resection (p = 0.010), those with a tumor volume exceeding 10 ml (p = 0.05), and those with Koos Grade 4 tumors (p = 0.02) had less likelihood of tumor control after SRS.
Although microsurgical resection remains the primary management choice in patients with low comorbidities, most vestibular schwannomas with a maximum diameter less than 4 cm and without significant mass effect can be managed satisfactorily with Gamma Knife radiosurgery.
立体定向放射外科(SRS)是治疗小中型前庭神经鞘瘤的重要治疗方法。为了评估 SRS 在较大肿瘤中的潜在作用,作者回顾了他们的近期经验。
1994 年至 2008 年,65 例最大管内直径 3-4cm 的前庭神经鞘瘤患者(中位肿瘤体积 9ml)接受了伽玛刀手术。17 例(26%)曾行切除术。
中位随访时间为 36 个月(1-146 个月)。在首次计划的 6 个月影像学随访时,5 例肿瘤(8%)略有增大,53 例(82%)肿瘤大小稳定,7 例(11%)肿瘤缩小。2 例(3%)患者因症状进展在 6 个月内行切除术。2 年后,2 次 SRS 后共 63 例肿瘤中,16 例(25%)肿瘤体积减少超过 50%,22 例(35%)肿瘤体积减少 10-50%,18 例(29%)肿瘤体积稳定(体积变化<10%),7 例(11%)肿瘤体积增大(其中 5 例患者行切除术,1 例患者行再次 SRS)。22 例术前听力良好的患者中,18 例(82%)在 SRS 后 2 年以上仍有可接受的听力。3 例(5%)出现症状性脑积水,行脑室-腹腔分流术。4 例(6%)出现三叉神经感觉功能障碍,1 例(2%)出现轻度面瘫(House-Brackmann 分级 II 级)。单因素分析显示,有既往切除术史(p=0.010)、肿瘤体积>10ml(p=0.05)和 Koos 分级为 4 级(p=0.02)的患者 SRS 后肿瘤控制的可能性较小。
尽管显微切除术仍然是低合并症患者的主要治疗选择,但大多数最大直径小于 4cm 且无明显肿块效应的前庭神经鞘瘤可以通过伽玛刀放射外科满意地治疗。